Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
Fiche publication
Date publication
mai 2021
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr KIM Stephano
Tous les auteurs :
Metges JP, Genet D, Tougeron D, Ligeza C, Ducreux M, Borg C, Guimbaud R, Phelip JM, Dourthe LM, Kim S
Lien Pubmed
Résumé
We report real-world evidence with regorafenib in previously treated metastatic colorectal cancer from the French cohort of the international, prospective, observational CORRELATE study. Patients receiving regorafenib according to French health authority approval were included. The primary end point was treatment-emergent adverse events. Overall survival and progression-free survival were secondary end points. Two hundred and forty-two patients (61% male, median age: 66 years) were enrolled. The most common grade ≥3 drug-related treatment-emergent adverse events were hand-foot skin reaction (10.3%), asthenia/fatigue (9.9/1.2%) and hypertension (6.2%). Median overall survival and progression-free survival were 6.8 (95% CI: 6.3-7.6) and 2.8 months (95% CI: 2.6-3.0), respectively. The real-world safety and effectiveness data of regorafenib in metastatic colorectal cancer in France align with findings from Phase III clinical trials and the global CORRELATE population.
Mots clés
CORRELATE, colorectal cancer, metastatic, multikinase inhibitor, regorafenib
Référence
Future Oncol. 2021 May 20;: